Spliceor
Cancer gene therapy platform to progress curative treatments for the most aggressive cancers that respond poorly to alternative treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Spliceor is an early-stage biotechnology firm that emerged from the Department of Medicine at the University of Cambridge, U.K. . The company, founded on August 20, 2020, is focused on the research and development of gene therapies for aggressive cancers that have shown resistance to current treatment methods. The co-founders are Andrew Lever and Carin Ingemarsdotter.
The company's core technology centers on RNA trans-splicing to create therapeutic effector mRNA within specific cell types, a process enhanced by machine learning using both public and proprietary datasets for design optimization. This approach allows for the creation of chimeric mRNA by joining exons from different pre-mRNA molecules, potentially leading to the expression of proteins with new, therapeutic functions. Spliceor's primary mission is to develop tumor-selective and well-tolerated gene therapies. The initial focus is on treatments for liver and pancreatic cancers, with the underlying platform technology holding potential for applications in other diseases beyond oncology.
As a private, pre-clinical stage company, Spliceor's business model is centered on research and development aimed at progressing its therapies toward clinical trials. The company has successfully secured funding to advance its work. In March 2021, it raised $695K in a seed round from investors including Amadeus Capital Partners, Cambridge Enterprise Ventures, Cancer Research Horizons, and Start Codon. More recently, in July 2025, Spliceor received an investment from the Cell and Gene Therapy (CGT) Catapult as part of the Cross-Catapult Investment Pilot. This funding is designated to accelerate the pre-clinical development of its gene therapy for liver cancer, expand the team, and further validate the treatment platform.
Keywords: gene therapy, RNA trans-splicing, oncology, biotechnology, cancer treatment, University of Cambridge spinout, liver cancer, pancreatic cancer, therapeutic mRNA, pre-clinical, cell therapy, molecular biology, genetic engineering, drug development, life sciences, healthcare innovation, therapeutic platform, cancer research, chimeric mRNA, targeted therapy